Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELOBiotechnology
-$0.04 today
- Market cap
- $50.84M
- Beta
- -0.24
- P/E (TTM)
- -3.8
- EPS (TTM)
- -$0.27
Volume 0.17M
Average 0.13M
TELO EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Telomir Pharmaceuticals, Inc. Common StockNASDAQ: TELO
EBITDA · Q1 FY2026 · quarter ended Mar 2026
EBITDA remains negative
Q1 FY2026 EBITDA was -$989.69K, compared with -$2.18M a year earlier. Trailing-twelve-month EBITDA was -$9.22M.
Context
- EBITDA increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly EBITDA holds near -$989.69K or moves back toward the trailing-twelve-month quarterly average of -$2.31M.
Sources:Income StatementText generated from reported figures; not investment advice.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (10.41M) USD
- Year-over-year change
- -21794.2%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (10.41M) | -21794.2% |
| FY2024 | 2024-12-31 | 48K | +100.4% |
| FY2023 | 2023-12-31 | (11.43M) | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
EBITDA vs competitors
How TELO compares with its peers on the latest reported figures
- TELO's LTM Mar 2026 EBITDA of -$9.22M is the highest of the 6 companies compared; the peer median is -$25.09M.
- Its year-over-year change of +26.2% is the highest of 6, against a peer median of -40.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$9.22M | +26.2% | — | — | |
| LTM Mar 2026 | -$10.87M | -9.4% | — | 769.0% | |
| LTM Mar 2026 | -$18.95M | -40.5% | — | — | |
| LTM Mar 2026 | -$25.09M | +18.9% | — | — | |
| LTM Mar 2026 | -$89.9M | -1211.1% | — | — | |
| LTM Mar 2026 | -$147.92M | -653.3% | — | 97.9% | |
| Peer median (excluding TELO) | -$25.09M | -40.5% | — | 433.5% | |
Competitors are the stored peer set for TELO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 0 | 0 | 0 | 0 |
| Gross Margin | — | — | — | — | — |
| Research & Development | 126.49K | 833.21K | 1.57M | 2.24M | 2.44M |
| Selling, General & Admin | 11.64K | 20.94K | 600.19K | 9.64M | 8.1M |
| Operating Expenses | 138.13K | 854.15K | 3.94M | 12.24M | 10.54M |
| Depreciation & Amortization | 138.13K | 854.15K | 0 | 12.24M | 0 |
| EBITDA | 0 | 0 | (11.43M) | 48K | (10.41M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (138.13K) | (854.15K) | (3.94M) | (12.24M) | (10.54M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 0 | 0 | 0 | 48K | 125.64K |
| Interest Expense | 0 | 0 | 1.64M | (4.34M) | 0 |
| Other Income / Expenses | 0 | 0 | (9.13M) | (4.29M) | 125.64K |
| Income Before Tax | (138.13K) | (854.15K) | (13.07M) | (16.53M) | (10.41M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (138.13K) | (854.15K) | (13.07M) | (16.53M) | (10.41M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.00) | (0.03) | (0.44) | (0.56) | (0.33) |
| EPS (Diluted) | (0.00) | (0.03) | (0.44) | (0.56) | (0.33) |
| Weighted Avg Shares | 29.61M | 29.61M | 29.61M | 29.54M | 31.65M |
| Weighted Avg Shares (Diluted) | 29.61M | 29.61M | 29.61M | 29.54M | 31.65M |
Telomir Pharmaceuticals, Inc. Common Stock
NASDAQ:TELO
Intrinsic Alpha fair value
Locked
Current Price
$0.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.